The Real‐WorldObservational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months

利拉鲁肽 杜拉鲁肽 医学 2型糖尿病 内科学 艾塞那肽 观察研究
作者
Bruno Guerci,Francesco Giorgino,Hélène Sapin,Kristina S. Boye,Jérémie Lebrec,Marco Orsini Federici,Elke Heitmann,Anne Dib,Martin Füchtenbusch,Luis‐Emilio García‐Pérez
出处
期刊:Diabetes, Obesity and Metabolism [Wiley]
卷期号:24 (12): 2373-2382 被引量:2
标识
DOI:10.1111/dom.14823
摘要

The primary objective of the TROPHIES observational study is to estimate the duration of treatment on dulaglutide or liraglutide without a significant treatment change by 24 months in patients with type 2 diabetes (T2D) initiating their first injectable treatment with these glucagon-like peptide-1 receptor agonists (GLP-1 RAs). This manuscript presents 12-month interim data.TROPHIES is a prospective, non-comparative, observational study of patients with T2D in Europe, naïve to injectable antihyperglycaemic treatments and initiating dulaglutide or liraglutide. Data on clinical characteristics, GLP-1 RA persistence and treatment patterns of glucose-lowering medication were collected at initiation of first injectable therapy and by 12 months.By 12 months, 1014 dulaglutide and 991 liraglutide patients were eligible across France, Germany and Italy. Both cohorts presented a high probability [95% confidence interval (CI)] of GLP-1 RA persistence [dulaglutide, 0.88 (0.86 to 0.90); liraglutide, 0.83 (0.80 to 0.85)] and reduction in mean glycated haemoglobin percentage (95% CI) from baseline [dulaglutide, -1.18 (-1.27 to -1.08); liraglutide, -1.15 (-1.26 to -1.05)] with 48.2% of dulaglutide and 41.2% of liraglutide patients reaching their individualized glycated haemoglobin percentage target set by the physician at baseline. Mean weight (95% CI) change from baseline was -3.2 kg (-3.6 to -2.8) for dulaglutide and -3.4 kg (-3.9 to -3.0) for liraglutide. Slight changes in concomitant medications were observed compared with baseline.In the real-world setting, dulaglutide and liraglutide cohorts achieved good persistence with similarly improved glycaemic control that was accompanied by weight loss at 12 months, consistent with previous clinical trial results.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
丹丹发布了新的文献求助10
刚刚
秋风的应助被冷如松采纳,获得10
1秒前
顾矜的应助被manstein采纳,获得10
1秒前
1秒前
小五发布了新的文献求助10
2秒前
Ov5发布了新的文献求助10
2秒前
八笔完成签到 ,获得积分10
2秒前
2秒前
clumsy0125完成签到,获得积分10
3秒前
小李发布了新的文献求助10
3秒前
3秒前
轻飏完成签到,获得积分10
4秒前
淡然寒梅完成签到 ,获得积分10
6秒前
7秒前
啪啪啪发布了新的文献求助10
7秒前
峰成完成签到 ,获得积分10
7秒前
无限尔曼完成签到 ,获得积分10
7秒前
小丑恐龙发布了新的文献求助20
8秒前
ding的应助被espresso采纳,获得30
8秒前
9秒前
wang的应助被ychope采纳,获得20
10秒前
慕青的应助被单薄雪巧采纳,获得10
11秒前
111发布了新的文献求助10
11秒前
CodeCraft的应助被Ov5采纳,获得10
11秒前
111发布了新的文献求助10
12秒前
肆月完成签到 ,获得积分10
12秒前
njseu完成签到 ,获得积分10
12秒前
wangrch6完成签到,获得积分10
14秒前
噜噜噜完成签到,获得积分10
15秒前
祈祷spring发布了新的文献求助10
15秒前
认真初之完成签到,获得积分10
16秒前
ma驳回了晚晚的应助
16秒前
HY发布了新的文献求助10
16秒前
梦真完成签到,获得积分10
19秒前
19秒前
19秒前
CodeCraft的应助被XY采纳,获得10
20秒前
20秒前
乐乐的应助被Jiang采纳,获得10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193335
求助须知:如何正确求助?哪些是违规求助? 9579489
关于积分的说明 21865844
捐赠科研通 7792843
什么是DOI,文献DOI怎么找? 3437210
关于科研通互助平台的介绍 2560687
邀请新用户注册赠送积分活动 2483996